RET and cancer: There were more FLT3, FGFR1, and AKT1 mutations (p-value < 0.05) in nonhypermutated cancers, while there were more RET, CBL, and DDR2 mutations (p-value < 0.05) in hypermutated cancers (Figure 1B and Table S2).